The bill directs the Secretary of Health and Human Services to conduct or support research into earlier detection and intervention for uterine fibroids and to develop evidence-based strategies for use in clinical settings. It also authorizes HHS to award discretionary grants to States to run programs that increase early detection, provide patient navigation, pay for advanced gynecological imaging, and fund public awareness campaigns.
The measure targets disparities by prioritizing grant awards for programs serving socially vulnerable populations, and it separately authorizes research grants (including clinical trials) on disparities in pain control and intrauterine conditions such as Asherman’s syndrome. It requires biennial public reports to Congress summarizing grant-funded program results and research developments.
The bill does not specify funding levels or mandatory appropriations, leaving budgetary details to later action.
At a Glance
What It Does
Requires HHS to research and finalize evidence-based strategies to increase early detection of uterine fibroids, then—at the agency's discretion—award grants to States for programs that cover screening (including advanced imaging), patient navigation, implementation of the strategies, and outreach. Separately authorizes research grants on pain-disparity issues and intrauterine conditions.
Who It Affects
State health departments and their contracted providers, obstetrics/gynecology clinics and imaging centers, community-based organizations running awareness campaigns, researchers conducting clinical trials, and patients—particularly people in socially vulnerable populations at higher risk for fibroids.
Why It Matters
This is a focused federal push to move uterine-fibroid care toward earlier detection and coordinated intervention, with an explicit equity priority. For clinicians and payers it signals potential growth in screening, navigation services, and targeted research that could change standards of care and resource allocation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 2 makes HHS responsible for building the evidence base: the agency must conduct or support research into how to detect uterine fibroids earlier and intervene sooner, and then translate those findings into strategies that health care settings can implement. The bill requires the Secretary to finalize those strategies “as expeditiously as possible,” and directs that grantees under the grant program should be able to use them.
Section 3 creates the core grant authority. HHS may award grants to States to run programs focused on early detection and intervention and to fund public awareness and education.
The statute lists permissible uses: paying for screening procedures and advanced gynecological imaging, providing patient navigation, implementing the evidence-based strategies developed under section 2, and facilitating access to care. The grant authority is discretionary (the Secretary “may” award grants) and includes a statutory priority for proposals targeting geographic areas with socially vulnerable populations that face elevated fibroid risk.Section 4 authorizes separate research grants that can include clinical trials to study disparities in pain control and management in surgical fibroid treatment, and to study Asherman’s syndrome, intrauterine adhesions, and related intrauterine conditions.
That provision is framed to let HHS fund targeted scientific work that complements the programmatic grants to States.Section 5 imposes reporting duties: beginning two years after the first grant awards, HHS must report to Congress and publish publicly a biennial summary of grant program findings and results. Separately, the agency must publish a biennial report on research developments related to pain-control disparities and intrauterine conditions, with the first report due within two years of enactment.
The reports are intended to create a public record of what the grants and research produce and to inform future policy and practice.
The Five Things You Need to Know
The bill requires HHS to conduct or support research and to finalize evidence-based or evidence-informed early-detection strategies for uterine fibroids.
HHS may award discretionary grants to States to fund screening (including payment for advanced gynecological imaging), patient navigation, implementation of the HHS strategies, and public awareness campaigns.
The Secretary must give priority to State grant proposals that target geographic areas with socially vulnerable populations at elevated risk of developing uterine fibroids.
The statute authorizes research grants, including clinical trials, focused on disparities in pain control and management during fibroid surgical treatment and on intrauterine conditions such as Asherman’s syndrome.
HHS must submit and publish reports to Congress: a biennial summary of grant program findings beginning two years after the first awards, and a biennial research developments report beginning within two years of enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the Act's short title: the 'Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.' This is purely nominative but matters for citation and any cross-references in agency guidance or appropriation language.
Federal research and strategy development
Directs the Secretary to conduct or support research on increasing early detection and intervention for uterine fibroids and to formulate evidence-based or evidence‑informed strategies for health care settings. Practically, this creates a development pathway: research → codified strategies → availability for grantees to implement. The statutory phrase 'as expeditiously as possible' creates a departmental obligation to move quickly but does not set a hard deadline, leaving timing to HHS judgment and resource availability.
State grant program for detection, navigation, and outreach
Authorizes HHS to award grants to States to carry out programs that increase early detection and intervention and to run public awareness campaigns. The statute specifies permitted uses—screening and payment for advanced imaging, patient navigation services, implementation of the HHS strategies, and facilitating access to care—giving States flexibility to design multi-component programs. The provision makes grant awards discretionary ('may'), and it requires the Secretary to prioritize proposals targeting socially vulnerable areas, which will shape award criteria and outreach by HHS.
Targeted research on disparities and intrauterine conditions
Authorizes grants to support research, potentially including clinical trials, on disparities in pain control for surgical fibroid treatment and on intrauterine conditions (Asherman’s syndrome and related adhesions). This creates a complementary research track focused on postoperative outcomes and complications that could change clinical practice and postoperative care standards if the trials identify actionable interventions or reveal systematic disparities.
Biennial reporting to Congress and public disclosure
Requires two types of reports: (1) beginning two years after the initial grant awards and every two years thereafter, a public report summarizing programs and activities funded under the Act; and (2) beginning within two years of enactment and biennially thereafter, a report on research developments related to the specified disparities and intrauterine conditions. Both reports must be submitted to Congress and posted on HHS websites, creating recurring transparency and a documented evidence base to guide future funding decisions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with uterine fibroids in socially vulnerable communities — could see earlier detection, better navigation to care, and targeted outreach that reduces delays to treatment and addresses documented disparities.
- State health departments and community health centers — eligible to receive grant funds to expand screening, navigation, and outreach services and to implement evidence-based strategies developed by HHS.
- Clinical providers (OB/GYNs, radiology clinics) — may gain reimbursement support for advanced imaging and increased referrals, and access to HHS-developed strategies that standardize earlier detection and care pathways.
- Research institutions and investigators — would be eligible for grants and clinical-trial funding focused on pain-management disparities and intrauterine conditions, creating new research opportunities and data.
- Community-based organizations doing outreach and education — positioned to receive grant-funded contracts to run awareness campaigns in prioritized, high-risk areas.
Who Bears the Cost
- Federal budget (HHS appropriations) — the bill authorizes grant and research spending but contains no appropriation; actual costs depend on future appropriations decisions.
- State health agencies and providers — must build administrative capacity to apply for and manage grants and to scale up screening and navigation programs, which can require staff time and systems investment.
- Public and private payers (including Medicaid) — may face near-term increases in utilization and imaging costs as screening and access expand, even if long-term costs shift if invasive surgeries are reduced.
- HHS — responsible for rapidly developing strategies, running competitive grant programs, overseeing grantee performance, and producing biennial reports, all of which require staff and administrative resources.
- Health systems and imaging facilities — could see increased demand for advanced gynecological imaging, requiring capacity planning and potential capital or workforce investments.
Key Issues
The Core Tension
The central dilemma is advancing equitable early detection to reduce morbidity and disparities versus the risk of increasing short‑term costs and unnecessary interventions without clear funding, standardized clinical thresholds, or defined program metrics; success depends on HHS rulemaking, available appropriations, and careful design to avoid unintended overdiagnosis or uneven access.
The bill creates a framework—research, strategy development, grants, and reporting—but leaves critical implementation details to HHS rulemaking and appropriations. It authorizes funding and directs HHS action but does not set dollar amounts, grant formulae, award timing, or eligibility thresholds beyond a geographic-priority clause for 'socially vulnerable populations.' That gap means the program's scope, reach, and pace will hinge on subsequent appropriations and on how HHS defines key terms.
There are practical trade-offs the statute does not resolve. Expanding early detection often increases short-term utilization (imaging, follow-up visits, minimally invasive procedures) and could lead to overtreatment if screening is not tightly linked to evidence-based thresholds for intervention.
The bill attempts to mitigate that risk by requiring HHS-developed strategies, but it gives no enforcement mechanism to ensure grantees adopt or adhere to particular clinical thresholds. The research mandates (e.g., on pain-control disparities and Asherman’s syndrome) are important but depend on standardized outcome metrics, trial design decisions, and data collection systems that the bill does not prescribe.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.